Company: CERO
Filing Date: 2025-01-23
Form Type: 424B3
Source: 0001213900-25-005623
Chunk: 1

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-23
Form: 424B3
Chunk 1
---
us, and if there is any
inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on this Prospectus Supplement.

Our common stock and public warrants are listed on Nasdaq Global Market
and Nasdaq Capital Market (collectively, “Nasdaq”) under the symbols “CERO” and “CEROW,” respectively.
On January 21, 2025, the last quoted sale price of our common stock as reported on Nasdaq was $2.31 per share and the last quoted sale
price of our public warrants as reported on Nasdaq was $0.0154 per warrant.

We are an “emerging growth company” under applicable federal securities laws and will be subject to reduced public company reporting requirements.

Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in “Risk Factors” beginning on page 8 of the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or determined if the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this Prospectus Supplement is January 22, 2025.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or Section 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 17, 2025

CERO THERAPEUTICS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)</div>

| Delaware                        |     | 001-40877               |     | 87-1088814            |
| (State or other jurisdiction of 
 incorporation or organization)  |     | -Commission File Number |     | -I.R.S. Employer      
 Identification Number |

| 201 Haskins Way, Suite 230, South San Francisco, CA |     |     94080 |
| (Address of principal executive offices)            |     | -Zip Code |

<div align='center'>(650) 407-2376

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report)</div>

Check the appropriate box below